



Areacor Therapeutics plc
("Areacor" or the "Company")

Areacor to present at Oppenheimer Annual Healthcare MedTech & Services Conference

Cambridge, UK, 9 March 2026: Areacor Therapeutics plc (AIM: AREC), a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, will be presenting at the Oppenheimer 36th Annual Healthcare MedTech and Services Conference on 16 March. The Areacor team will also be attending the Advanced Technologies & Treatments for Diabetes (ATTD) conference, from 11-14 March. Full details for both events are below:

Oppenheimer 36th Annual Healthcare MedTech & Services Conference – 16-19 March 2026, online

Sarah Howell will be presenting on Areacor's lead programme AT278, the only ultra-concentrated, ultra-rapid acting insulin, designed to lower patient burden and improve outcomes for people with diabetes in combination with Automated Insulin Delivery (AID) Systems, at the Oppenheimer conference on March 16, 2026 at 9.20am EDT. Click [here](#) to register to watch the presentation. The presentation will also be made available on Areacor's website [here](#) after the event. David Ellam, CFO, will also be attending.

Advanced Technologies & Treatments for Diabetes (ATTD) - 11-14 March 2026, Barcelona

Sarah Howell (CEO), Jan Jezek (CSO) and David Gerring (CDO) will also be attending ATTD 2026. The conference brings clinicians, diabetes care providers, researchers, industry, investors, reimbursement authorities, and regulators together in order to collaborate to drive rapid progress in diabetes care.

For attendees at either conference interested in meeting the Areacor team, please email BD@arecor.com.

-ENDS-

For more information, please contact:

Areacor Therapeutics plc

Dr Sarah Howell, Chief Executive Officer
David Ellam, Chief Financial Officer

+44 (0) 1223 426060

info@arecor.com

**Singer Capital Markets Advisory LLP
(NOMAD and Broker)**

Phil Davies, James Fischer

+44 (0) 20 7496 3000

Vigo Consulting (Financial Communications)

Melanie Toyne-Sewell, Rozi Morris

+44 (0) 20 7390 0230

arecor@vigoconsulting.com

Vida Strategic Partners (US Investor Relations)

Stephanie Diaz

+1 (415) 675-7401

sdiaz@vidasp.com



Notes to Editors

About Areacor

Areacor Therapeutics plc is a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Its lead product is AT278, the only ultra-concentrated (500U/mL) ultra-rapid acting insulin, which enables disruptive drug delivery devices. It is being co-developed with Sequel Med Tech, a company commercialising state-of-the art insulin delivery devices. Areacor is also developing a novel oral delivery platform for peptides with its first validation target a GLP-1 receptor agonist.

The Company is quoted on AIM (AIM: AREC) and is based in Cambridge, UK. For further details please see www.areacor.com

About AT278

AT278 is a novel proprietary formulation of an existing insulin, designed to accelerate the absorption of insulin post injection even at very high concentrations (500U/mL). With its best-in-class profile, it has the potential to disrupt the market for insulin treatment as the first concentrated, yet very rapid acting insulin for the growing population of people with diabetes with high daily insulin needs as well as to act as a critical enabler in the development of next-generation, miniaturised longer wear automated insulin delivery (AID) systems.